Aro Biotherapeutics is a clinical stage biotech company specializing in the development of tissue-targeted genetic medicines, including a potential treatment for Pompe Disease and new therapies for autoimmune disorders, using their proprietary Centyrin-siRNA platform.

MBrace Therapeutics is a biopharmaceutical company developing a lead antibody-drug conjugate (ADC) candidate, MBRC-101, targeting the EphA5 receptor tyrosine kinase present in various cancers, with the recent completion of an $85 million Series B financing round.

MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapeutics for brain disorders, with plans to advance their pipeline programs, including ML-007C-MA, into Phase 2 trials for schizophrenia and Alzheimer's disease psychosis, as well as support their other pipeline programs.

Star Therapeutics is a biotechnology company that develops first-in-class antibody therapies, primarily for hematology and immunology, and also generates additional biotech companies focused on discovering and advancing novel antibody therapies.